NeuroproteXeon (NPXE) is a late clinical-stage pharmaceutical and medical device company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against brain cell death following acute neurologic injury. NPXE is currently preparing for a Phase III Clinical Trial in Out of Hospital Cardiac Arrest (OHCA) following a publication of positive Phase II Clinical Trial results in JAMA, March 2016.¹

NPXE is committed to becoming the leader in the development and commercialization of drug/device neuroprotective products that help prevent brain damage and improve mortality rates in patient populations experiencing acute injury to the brain.  NPXE believes xenon holds great promise due to its multiple mechanisms of action, extensive pre-clinical results² and positive Phase II clinical trial results which demonstrated a reduction in brain tissue damage and directionally better survival outcomes.

NPXE believes xenon is not only a noble gas, but is – moreover – a noble cause.

For inquiries and information on how to join us in our mission, please send us an email.

¹ Laitio et. al. ,JAMA. 2016;315(11):1120-1128. doi:10.1001/jama.2016.1933
² Maze, Can J Anesth/J Can Anesth. DOI 10.1007/s12630-015-0507-8